ZEVASKYN launch traction could force ABEO’s next sharp rerating

ABEO is no longer a binary approval story; it is now an early commercial execution story around ZEVASKYN. The clearest next upside catalyst is a near-term launch update showing continued acceleration in patient treatments, biopsy flow, QTC utilization, and reimbursement conversion after the strong Q1 print of $8.7M and three treated patients. With six treatment centers now active, strong cash of $168.3M, and very high short interest, another favorable commercial progress update could drive a meaningful rerating if investors gain confidence that quarterly revenue can keep scaling.

Abeona Therapeutics has transitioned into a commercial-stage rare-disease gene/cell therapy company, with ZEVASKYN now approved and launched for RDEB. That means the stock’s next meaningful move is less about FDA risk and more about whether management can prove that this complex autologous therapy can scale in the real world. The most important recent evidence was the May 13, 2026 Q1 update: three patients treated in Q1, $8.7M in product revenue versus $2.4M in Q4, six active Qualified Treatment Centers, and management commentary that more patients are being scheduled this quarter. That is the strongest current signal that launch traction may be building rather than stalling. For the next move higher, investors should focus on evidence that the treatment funnel is converting into a repeatable cadence: more biopsies collected, more manufacturing runs completed, more patients treated, and more QTCs activated or utilized. In rare-disease cell/gene therapy launches, the market often waits for proof that logistics and reimbursement are working before assigning a higher revenue multiple. ABEO now has the balance sheet to support this launch, reducing financing overhang relative to many microcap biotechs. That matters because it lets investors focus on adoption rather than dilution risk in the immediate term. The setup is also technically interesting because the stock trades around $5.32, well below analyst targets, while short float is extremely high at 34.2%. That creates the possibility that a strong commercial update could trigger both fundamental rerating and forced covering. The main risk is that launch complexity remains high: site readiness, payer approvals, manufacturing throughput, and patient scheduling can all slow adoption. Still, the best-supported next catalyst is a company update in the coming weeks that reinforces durable launch momentum. If that happens, ABEO could revisit the upper end of its recent trading range and potentially break toward the mid-$7s.